Medincell SA
PAR:MEDCL

Watchlist Manager
Medincell SA Logo
Medincell SA
PAR:MEDCL
Watchlist
Price: 16.76 EUR Market Closed
Market Cap: 490.1m EUR
Have any thoughts about
Medincell SA?
Write Note

Medincell SA
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medincell SA
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Medincell SA
PAR:MEDCL
PP&E Net
€5.4m
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Sanofi SA
PAR:SAN
PP&E Net
€11.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
PP&E Net
€594.2m
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Vetoquinol SA
PAR:VETO
PP&E Net
€87.6m
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
6%
Virbac SA
PAR:VIRP
PP&E Net
€381.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
PP&E Net
€147m
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
0%
No Stocks Found

Medincell SA
Glance View

Market Cap
487.2m EUR
Industry
Pharmaceuticals

MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

MEDCL Intrinsic Value
21.71 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Medincell SA's PP&E Net?
PP&E Net
5.4m EUR

Based on the financial report for Mar 31, 2024, Medincell SA's PP&E Net amounts to 5.4m EUR.

What is Medincell SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
10%

Over the last year, the PP&E Net growth was -15%. The average annual PP&E Net growth rates for Medincell SA have been 12% over the past three years , 10% over the past five years .

Back to Top